Avid Bioservices to Report Financial Results for Quarter and Fiscal Year Ended April 30, 2024, After Market Close on July 2, 2024

7/1/24 7:00:21 AM ET

Biotechnology: Pharmaceutical Preparations

Health Care

Get the next $CDMO alert in real time by email

TUSTIN, Calif., July 01, 2024 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient lives by providing high quality services to biotechnology and pharmaceutical companies, today announced that it will report financial results for the quarter and fiscal year ended April 30, 2024, on July 2, 2024, after market close and will host a webcast at 1:30 PM Pacific Time (4:30 PM Eastern Time). Members of Avid's senior management will discuss financial results for the quarter and fiscal year ended April 30, 2024, and review recent corporate developments.

To listen to the live webcast, or access the archived webcast, please visit: http://ir.avidbio.com/investor-events.

About Avid Bioservices, Inc.

Avid Bioservices (NASDAQ:CDMO) is a dedicated contract development and manufacturing organization (CDMO) focused on development and CGMP manufacturing of biologics. The company provides a comprehensive range of process development, CGMP clinical and commercial manufacturing services for the biotechnology and biopharmaceutical industries. With more than 30 years of experience producing biologics, Avid's services include CGMP clinical and commercial drug substance manufacturing, bulk packaging, release and stability testing and regulatory submissions support. For early-stage programs the company provides a variety of process development activities, including cell line development, upstream and downstream development and optimization, analytical methods development, testing and characterization. The scope of our services ranges from standalone process development projects to full development and manufacturing programs through commercialization. www.avidbio.com

Contacts:
Stephanie Diaz (Investors)
Vida Strategic Partners
415-675-7401
[email protected]

Tim Brons (Media)
Vida Strategic Partners
415-675-7402
[email protected]

Get the next $CDMO alert in real time by email

Recent Analyst Ratings for

$CDMO

Date	Price Target	Rating	Analyst
9/28/2023		Mkt Perform	William Blair
3/14/2023	$20.00	Sector Weight → Overweight	KeyBanc Capital Markets
3/9/2022	$31.00 → $28.00	Overweight	Stephens & Co.
12/8/2021	$29.00 → $35.00	Buy	Craig-Hallum
12/8/2021	$27.00 → $32.00	Outperform	RBC Capital
12/8/2021		Overweight → Sector Weight	Keybanc
6/30/2021	$21.00 → $29.00	Buy	Craig-Hallum
6/30/2021	$21.00 → $27.00	Outperform	RBC Capital

More analyst ratings

Avid Bioservices to Report Financial Results for Quarter and Fiscal Year Ended April 30, 2024, After Market Close on July 2, 2024

Chat with this insight

Recent Analyst Ratings for $CDMO

$CDMO Large Ownership Changes

This live feed shows all institutional transactions in real time.

Amendment: SEC Form SC 13G/A filed by Avid Bioservices Inc.

Amendment: SEC Form SC 13G/A filed by Avid Bioservices Inc.

Amendment: SEC Form SC 13G/A filed by Avid Bioservices Inc.

$CDMO Market Insights

Live Market Insights

Why Avid Bioservices Stock Is Moving Higher Wednesday

Avid Bioservices shares are trading higher after the company reported better-than-expected Q4 sales results.

RBC Capital Reiterates Outperform on Avid Bioservices, Maintains $8 Price Target

$CDMO Leadership Updates

Live Leadership Updates

Uber Technologies, Jabil and Builders FirstSource Set to Join S&P 500; Others to Join S&P MidCap 400 and S&P SmallCap 600

STERIS Appoints Esther M. Alegria, Ph.D. to Board of Directors

Avid Bioservices Appoints Oksana Lukash as Vice President, People

$CDMO Press Releases

Fastest customizable press release news feed in the world

$CDMO Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

Avid Bioservices to be Acquired by GHO Capital Partners and Ampersand Capital Partners in $1.1 Billion Transaction

Avid Bioservices to Participate in Craig-Hallum Bioprocessing Conference

Avid Bioservices Reports Financial Results for First Quarter Ended July 31, 2024

Hancock Richard B bought $202,036 worth of shares (38,803 units at $5.21), increasing direct ownership by 49% to 117,563 units (SEC Form 4)

Hancock Richard B converted options into 9,612 shares and bought $134,734 worth of shares (23,000 units at $5.86), increasing direct ownership by 71% to 78,760 units (SEC Form 4)

SEC Form 4: Carleone Joseph bought $190,696 worth of shares (20,000 units at $9.53), increasing direct ownership by 27% to 93,956 units

$CDMO Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

Chief Commercial Officer Kwietniak Matthew R. converted options into 335 shares and sold $1,208 worth of shares (119 units at $10.15), increasing direct ownership by 0.86% to 25,407 units (SEC Form 4)

Chief Operations Officer Richieri Richard A. converted options into 5,968 shares and sold $22,432 worth of shares (2,232 units at $10.05), increasing direct ownership by 10% to 37,704 units (SEC Form 4)

Chief Commercial Officer Kwietniak Matthew R. converted options into 2,763 shares and sold $9,869 worth of shares (982 units at $10.05), increasing direct ownership by 8% to 25,191 units (SEC Form 4)

$CDMO Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

William Blair initiated coverage on Avid Bioservices

Avid Bioservices upgraded by KeyBanc Capital Markets with a new price target

Stephens & Co. reiterated coverage on Avid Bioservices with a new price target

$CDMO Financials

Live finance-specific insights

Avid Bioservices Reports Financial Results for First Quarter Ended July 31, 2024

Avid Bioservices to Report Financial Results for First Quarter of Fiscal Year 2025 After Market Close on September 9, 2024

Avid Bioservices Reports Financial Results for Fourth Quarter and Fiscal Year Ended April 30, 2024

$CDMO SEC Filings

SEC Form DEFA14A filed by Avid Bioservices Inc.

Avid Bioservices Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Regulation FD Disclosure, Financial Statements and Exhibits

SEC Form DEFA14A filed by Avid Bioservices Inc.

Recent Analyst Ratings for
$CDMO

$CDMO
Large Ownership Changes

$CDMO
Market Insights

$CDMO
Leadership Updates

$CDMO
Press Releases

$CDMO
Insider Purchases

$CDMO
Insider Trading

$CDMO
Analyst Ratings

$CDMO
Financials

$CDMO
SEC Filings